COMING NEXT:

• Join us on 20th August (4:30 - 6:30pm) for our online event “Idea Evaluation: Lab to Market”. Do you have a research idea that you would like to commercialize? How would you go about it? Have you ever considered the commercial value of a product created / inspired from your research findings? What does the industry or the consumer actually need and who will pay for the product? What do you need to productize your research and solve a problem for the end customer? How can you reach your customers efficiently and get high market penetration? What is a Minimum Viable Product (MVP)? Does filing a patent mean you can't publish your research? If you are unsure how to answer these questions, this BPEP workshop will help! 
• Registration link: bit.ly/bpep-lab2market
  

• We are happy to announce the launch of a scholarship program to Postdocs and Visiting Scholars (VSPA affiliates) to explore launching startups that are based on research produced at UC Berkeley. The scholarship ($500) will help access resources provided by qb3 Startup in a box program. From incorporation to operation to growth, this program provides support and resources to entrepreneurs, in addition to access to their SBIR workshops. This scholarship program is limited to UC Berkeley VSPA affiliates with active appointments, who have a Ph.D. degree. Additional preference will be given to applicants who demonstrate their service to the entrepreneurial community at UC Berkeley. The scholarship program is enabled by a generous sponsorship by the Visiting Scholars and Postdoctoral Affairs Program (VSPA). Thanks to Yvette Lane-Newton, the Director of the VSPA , who has been instrumental in making this happen.
• Link to application: https://forms.gle/bZcLMd6FEYnE58Gy6

• We are extremely pleased to announce that Bacchus Therapeutics, founded by Arvin Gouw (Former Chair, BPEP) has been awarded the AbbVie Golden Ticket. Bacchus Therapeutics is a biotech company developing novel compounds that exploit cancer's hypermetabolic state by targeting cancer-specific metabolic pathways. Their proprietary compounds cause regression of incurable MYC cancers and prolong survival in our preclinical mouse models bearing human tumors.